

BEST AVAILABLE COPY

10/8/4, 1998
updated Search
L/Cook 6/5/06

d his

(FILE 'HOME' ENTERED AT 10:00:26 ON 05 JUN 2006)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 10:00:39 ON 05
JUN 2006

L1 18031 S PHOSPHOCHOLINE?
L2 14387 S PHOSPHORYLCHOLINE?
L3 2628 S L1 AND (PLATELET ACTIVATING FACTOR)
L4 1252 S L2 AND (PLATELET ACTIVATING FACTOR)
L5 89 S L3 AND ANTIBOD?
L6 56 S L4 AND ANTIBOD?
L7 34 DUPLICATE REMOVE L5 (55 DUPLICATES REMOVED)
L8 32 DUPLICATE REMOVE L6 (24 DUPLICATES REMOVED)
L9 22 S L7 AND PD<1998
L10 20 S L8 AND PD<1998
L11 0 S L9 AND L10
L12 3076 S (PLATELET ACTIVATING FACTOR) AND ANTIBOD?
L13 56 S L12 AND L2

=>

d his

(FILE 'HOME' ENTERED AT 10:00:26 ON 05 JUN 2006)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 10:00:39 ON 05
JUN 2006

L1 18031 S PHOSPHOCHOLINE?
L2 14387 S PHOSPHORYLCHOLINE?
L3 2628 S L1 AND (PLATELET ACTIVATING FACTOR)
L4 1252 S L2 AND (PLATELET ACTIVATING FACTOR)
L5 89 S L3 AND ANTIBOD?
L6 56 S L4 AND ANTIBOD?
L7 34 DUPLICATE REMOVE L5 (55 DUPLICATES REMOVED)
L8 32 DUPLICATE REMOVE L6 (24 DUPLICATES REMOVED)
L9 22 S L7 AND PD<1998
L10 20 S L8 AND PD<1998
L11 0 S L9 AND L10
L12 3076 S (PLATELET ACTIVATING FACTOR) AND ANTIBOD?
L13 56 S L12 AND L2

=>

ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:589360 CAPLUS

DN 113:189360

ED Entered STN: 23 Nov 1990

TI **Antibodies to platelet-activating factor**

AU Karasawa, Ken; Satoh, Noriko; Hongo, Toshio; Setaka, Morio; Mowri, Hiroomi; Takano, Tatsuya; Hashimoto, Shunichi; Ikegami, Shiro; Fujita, Kagari; et al.

CS Fac. Pharm. Sci., Teikyo Univ., Sagamiko, 199-01, Japan

SO Trends Pharmacol. Res. Platelet Act. Factor (PAF) Jpn., Proc. Symp. Probl. PAF, 11th (1988), Meeting Date 1987, 138-46. Editor(s): Ogura, Yasumi; Kisara, Kensaku. Publisher: Ishiyaku EuroAmerica, Tokyo, Japan. CODEN: 56ULA2

DT Conference

LA English

CC 15-3 (Immunochemistry)

AB Specific **antibodies to platelet-activating factor (PAF)** were prepared by immunizing rabbits with a hapten-bovine serum albumin (BSA) conjugate. As hapten a synthetic PAF derivative was used which is resistant to enzymic inactivation by plasma or tissues and which can bind to BSA through covalent bonding at the ω -position of the alkyl side chain. **Antibody** activity was determined by ELISA. Anti-PAF IgG reacted strongly with PAF. By means of the ELISA inhibition assay, **antibodies** did not cross-react with **phosphocholine** glycerophosphocholine, dilaurylglycerophosphocholine, or PAF analogs which have ethanolamine-type polar head groups instead of choline groups. The monoclonal **antibodies** were also produced in Balb/c mouse using the same immunizing method. When PAF was incubated with monoclonal **antibodies** and protein A Sepharose, supernatant did not cause rabbit platelet aggregation. The specificity and sensitivity of the mouse monoclonal **antibodies** were compared with those of rabbit polyclonal **antibodies**.

ST **platelet activating factor antibody**

IT Immunoglobulins

RL: FORM (Formation, nonpreparative)
(G, formation of, to **platelet-activating factor**, synthetic hapten induction of)

IT **Antibodies**

RL: FORM (Formation, nonpreparative)
(monoclonal, formation of, to **platelet-activating factor**, synthetic hapten induction of)

IT 65154-06-5, Blood **platelet-activating factor**

RL: BIOL (Biological study)
(**antibodies** to, synthetic analog hapten in formation of)

IT 130126-32-8

RL: BIOL (Biological study)
(as hapten for **antibody** formation to **platelet-activating factor**)

ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:589360 CAPLUS

DN 113:189360

ED Entered STN: 23 Nov 1990

TI **Antibodies to platelet-activating factor**

AU Karasawa, Ken; Satoh, Noriko; Hongo, Toshio; Setaka, Morio; Mowri, Hiroomi; Takano, Tatsuya; Hashimoto, Shunichi; Ikegami, Shiro; Fujita, Kagari; et al.

CS Fac. Pharm. Sci., Teikyo Univ., Sagamiko, 199-01, Japan

SO Trends Pharmacol. Res. Platelet Act. Factor (PAF) Jpn., Proc. Symp. Probl. PAF, 11th (1988), Meeting Date 1987, 138-46. Editor(s): Ogura, Yasumi; Kisara, Kensaku. Publisher: Ishiyaku EuroAmerica, Tokyo, Japan. CODEN: 56ULA2

DT Conference

LA English

CC 15-3 (Immunochemistry)

AB **Specific antibodies to platelet-activating factor (PAF)** were prepared by immunizing rabbits with a hapten-bovine serum albumin (BSA) conjugate. As hapten a synthetic PAF derivative was used which is resistant to enzymic inactivation by plasma or tissues and which can bind to BSA through covalent bonding at the ω -position of the alkyl side chain. **Antibody** activity was determined by ELISA. Anti-PAF IgG reacted strongly with PAF. By means of the ELISA inhibition assay, **antibodies** did not cross-react with **phosphocholine** glycerophosphocholine, dilaurylglycerophosphocholine, or PAF analogs which have ethanolamine-type polar head groups instead of choline groups. The monoclonal **antibodies** were also produced in Balb/c mouse using the same immunizing method. When PAF was incubated with monoclonal **antibodies** and protein A Sepharose, supernatant did not cause rabbit platelet aggregation. The specificity and sensitivity of the mouse monoclonal **antibodies** were compared with those of rabbit polyclonal **antibodies**.

ST **platelet activating factor antibody**

IT Immunoglobulins

RL: FORM (Formation, nonpreparative)
(G, formation of, to **platelet-activating factor**, synthetic hapten induction of)

IT **Antibodies**

RL: FORM (Formation, nonpreparative)
(monoclonal, formation of, to **platelet-activating factor**, synthetic hapten induction of)

IT 65154-06-5, Blood **platelet-activating factor**

RL: BIOL (Biological study)
(**antibodies** to, synthetic analog hapten in formation of)

IT 130126-32-8

RL: BIOL (Biological study)
(as hapten for **antibody** formation to **platelet-activating factor**)

ANSWER 7 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:91686 CAPLUS

DN 110:91686

ED Entered STN: 17 Mar 1989

TI Antigenic analogs of **platelet-activating factor** (PAF), production of the analogs and **antibodies** to them, and PAF immunoassays

IN Baldo, Brian Angelo; Redmond, John William

PA University of Sydney, Australia; Macquarie University; Royal North Shore Hospital

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07F009-10

ICS G01N033-92; C07K015-12

CC 9-10 (Biochemical Methods)

Section cross-reference(s): 7, 23, 29

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--------------------|------|----------|-----------------|--------------|
| PI | WO 8705904 | A1 | 19871008 | WO 1987-AU84 | 19870324 <-- |
| | W: AU, JP, KR, US | | | | |
| | RW: DE, FR, GB, IT | | | | |
| | AU 8772097 | A1 | 19871020 | AU 1987-72097 | 19870324 <-- |
| | AU 607698 | B2 | 19910314 | | |
| | EP 299965 | A1 | 19890125 | EP 1987-902318 | 19870324 <-- |
| | R: DE, FR, GB, IT | | | | |
| | JP 01502584 | T2 | 19890907 | JP 1987-502157 | 19870324 <-- |
| | IL 82057 | A1 | 19941111 | IL 1987-82057 | 19870331 <-- |
| | US 5061626 | A | 19911029 | US 1987-156923 | 19871124 <-- |
| PRAI | AU 1986-5175 | A | 19860324 | | |
| | WO 1987-AU84 | A | 19870324 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|-------------|-------|--|
| WO 8705904 | ICM | C07F009-10 |
| | ICS | G01N033-92; C07K015-12 |
| | IPCI | C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; G01N0033-92 [ICS,4]; C07K0015-12 [ICS,4] |
| | IPCR | A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*] |
| AU 8772097 | IPCI | C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; G01N0033-92 [ICS,4]; C07K0015-12 [ICS,4] |
| | IPCR | A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*] |
| EP 299965 | IPCI | C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; G01N0033-92 [ICS,4]; C07K0015-12 [ICS,4] |
| | IPCR | A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*] |
| JP 01502584 | IPCI | C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; A61K0039-395 [ICS,4]; C07K0003-08 [ICS,4]; C07K0015-12 [ICS,4]; G01N0033-53 [ICS,4] |
| IL 82057 | IPCI | C07K0015-06 [ICM,5]; C07K0007-00 [ICS,5]; C07H0005-06 [ICS,5]; C07H0005-00 [ICS,5,C*]; C07F0009-10 [ICS,5]; C07F0009-00 [ICS,5,C*]; C08B0037-00 [ICS,5]; G01N0033-53 [ICS,5] |
| US 5061626 | IPCI | C12N0011-00 |

IPCR A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
 NCL 435/174.000; 435/192.000; 435/199.000; 435/207.000; 436/545.000; 436/546.000; 530/345.000; 530/402.000; 530/403.000; 530/404.000; 530/406.000; 530/408.000; 530/409.000; 530/410.000; 554/080.000; 558/169.000; 558/172.000

OS MARPAT 110:91686
 GI



AB PAF analogs I [R1 = C2-25 alkylene or alkenylene linking group substituted by radioactive I and X = H; or R1 = C2-25 alkylene, alkenylene, alkynylene, optionally 3H- or radioactive I-substituted, and X = CHO, di(C1-6 alkoxy)methyl, CO₂H, NCO, OH, SH, N-(C1-6 alkyl)amino, N,N-di(C1-6 alkyl)amino, AB; A = linking group (NR₆, CO₂, O₂C, CONR₆, NR₆CO, NHCSNH, SS; R₆ = H, C1-6 alkyl); B = protein, peptide, carbohydrate, lipid of ≥2000 mol. weight, label; R₂-R₅ = C1-6 alkyl] are prepared and are useful in production of anti-PAF **antibodies** or as reagents in PAF immunoassays. 2-O-Acetyl-1-O-(6'-oxohexyl)-sn-glycerol-3-phosphorylcholine [prepared from cyclohexanone and HC(OMe)₃ in 8 steps] was conjugated to methylated bovine serum albumin. The conjugate was used to prepare rabbit anti-PAF serum which was used in an assay for PAF.

ST **platelet activating factor analog**
antibody immunoassay; acetyloxohexylglycerylphosphorylcholine albumin conjugate; **phosphorylcholine** acetyloxohexylglyceryl albumin conjugate

IT Veterinary medicine
 (blood **platelet-activating factor** determination
 by immunoassay in relation to)

IT Blood analysis
 Body fluid
 (blood **platelet-activating factor** determination
 in, by immunoassay, antigenic and labeled analogs for)

IT Detergents
 Lecithins
 Ethers, uses and miscellaneous
 Polyoxyalkylenes, uses and miscellaneous
 RL: ANST (Analytical study)
 (in blood **platelet-activating factor**
 determination in body fluid by immunoassay)


IT **Antibodies**
 RL: ANST (Analytical study)
 (to blood **platelet-activating factor**
 analogs)

IT Ethers, biological studies
 RL: USES (Uses)
 (Ph, in blood **platelet-activating factor**
 determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, compounds

IPCR A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
 NCL 435/174.000; 435/192.000; 435/199.000; 435/207.000; 436/545.000; 436/546.000; 530/345.000; 530/402.000; 530/403.000; 530/404.000; 530/406.000; 530/408.000; 530/409.000; 530/410.000; 554/080.000; 558/169.000; 558/172.000

OS MARPAT 110:91686
 GI



AB PAF analogs I [R1 = C2-25 alkylene or alkenylene linking group substituted by radioactive I and X = H; or R1 = C2-25 alkylene, alkenylene, alkynylene, optionally 3H- or radioactive I-substituted, and X = CHO, di(C1-6 alkoxy)methyl, CO2H, NCO, OH, SH, N-(C1-6 alkyl)amino, N,N-di(C1-6 alkyl)amino, AB; A = linking group (NR6, CO2, O2C, CONR6, NR6CO, NHCSNH, SS; R6 = H, C1-6 alkyl); B = protein, peptide, carbohydrate, lipid of ≥ 2000 mol. weight, label; R2-R5 = C1-6 alkyl] are prepared and are useful in production of anti-PAF **antibodies** or as reagents in PAF immunoassays. 2-O-Acetyl-1-O-(6'-oxohexyl)-sn-glycerol-3-phosphorylcholine [prepared from cyclohexanone and HC(OMe)3 in 8 steps] was conjugated to methylated bovine serum albumin. The conjugate was used to prepare rabbit anti-PAF serum which was used in an assay for PAF.

ST **platelet activating factor analog**
antibody immunoassay; acetyloxohexylglycerylphosphorylcholine albumin conjugate; **phosphorylcholine** acetyloxohexylglyceryl albumin conjugate

IT Veterinary medicine
 (blood **platelet-activating factor** determination by immunoassay in relation to)
 IT Blood analysis
 Body fluid
 (blood **platelet-activating factor** determination in, by immunoassay, antigenic and labeled analogs for)

IT Detergents
 Lecithins
 Ethers, uses and miscellaneous
 Polyoxyalkylenes, uses and miscellaneous
 RL: ANST (Analytical study)
 (in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT **Antibodies**
 RL: ANST (Analytical study)
 (to blood **platelet-activating factor** analogs)

IT Ethers, biological studies
 RL: USES (Uses)
 (Ph, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, compounds

RL: ANST (Analytical study)
 (acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters
 RL: ANST (Analytical study)
 (alditols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Castor oil
 RL: ANST (Analytical study)
 (alkoxylated, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Albumins, compounds
 Carbohydrates and Sugars, compounds
 Lipids, compounds
 Peptides, compounds
 Proteins, specific or class
 RL: ANST (Analytical study)
 (conjugates, with glycerylphosphorylcholine derivative, as antigenic blood **platelet-activating factor** analogs)

IT Enzymes
 RL: ANST (Analytical study)
 (conjugates, with glycerylphosphorylcholine derivs., as labeled blood **platelet-activating factor** analogs)

IT Fatty acids, esters
 RL: ANST (Analytical study)
 (esters, with hexitol anhydrides, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters
 RL: ANST (Analytical study)
 (hexitols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Alcohols, compounds
 RL: ANST (Analytical study)
 (long-chain, alkoxylated, acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT **Antibodies**
 RL: ANST (Analytical study)
 (monoclonal, to blood **platelet-activating factor** analogs)

IT Detergents
 (nonionic, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT 25104-18-1D, Polylysine, glycerylphosphorylcholine derivative conjugates
 38000-06-5D, Polylysine, glycerylphosphorylcholine derivative conjugates
 119142-22-2D, albumin and polylysine conjugates
 RL: ANST (Analytical study)
 (as antigenic blood **platelet-activating factor** analogs)

IT 9005-64-5, Tween 20
 RL: ANST (Analytical study)
 (blood **platelet-activating factor** acetylhydrolase inactivation by, blood **platelet-activating factor** immunoassay in relation to)

IT 51-45-6D, 1H-Imidazole-4-ethanamine, iodine-125-labeled 51-67-2D, iodine-125-labeled 1080-06-4D, iodine-125-labeled
 RL: ANST (Analytical study)
 (blood **platelet-activating factor** analogs labeled with, for immunoassay)

IT 65154-06-5, Blood **platelet-activating factor**
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, by immunoassay, antigenic and labeled analogs for)

RL: ANST (Analytical study)
 (acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters
 RL: ANST (Analytical study)
 (alditols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Castor oil
 RL: ANST (Analytical study)
 (alkoxylated, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Albumins, compounds
 Carbohydrates and Sugars, compounds
 Lipids, compounds
 Peptides, compounds
 Proteins, specific or class
 RL: ANST (Analytical study)
 (conjugates, with glycerylphosphorylcholine derivative, as antigenic blood **platelet-activating factor** analogs)

IT Enzymes
 RL: ANST (Analytical study)
 (conjugates, with glycerylphosphorylcholine derivs., as labeled blood **platelet-activating factor** analogs)

IT Fatty acids, esters
 RL: ANST (Analytical study)
 (esters, with hexitol anhydrides, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters
 RL: ANST (Analytical study)
 (hexitols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Alcohols, compounds
 RL: ANST (Analytical study)
 (long-chain, alkoxylated, acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT **Antibodies**
 RL: ANST (Analytical study)
 (monoclonal, to blood **platelet-activating factor** analogs)

IT Detergents
 (nonionic, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT 25104-18-1D, Polylysine, glycerylphosphorylcholine derivative conjugates
 38000-06-5D, Polylysine, glycerylphosphorylcholine derivative conjugates
 119142-22-2D, albumin and polylysine conjugates
 RL: ANST (Analytical study)
 (as antigenic blood **platelet-activating factor** analogs)

IT 9005-64-5, Tween 20
 RL: ANST (Analytical study)
 (blood **platelet-activating factor** acetylhydrolase inactivation by, blood **platelet-activating factor** immunoassay in relation to)

IT 51-45-6D, 1H-Imidazole-4-ethanamine, iodine-125-labeled 51-67-2D, iodine-125-labeled 1080-06-4D, iodine-125-labeled
 RL: ANST (Analytical study)
 (blood **platelet-activating factor** analogs labeled with, for immunoassay)

IT 65154-06-5, Blood **platelet-activating factor**
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, by immunoassay, antigenic and labeled analogs for)

IT 108-95-2D, Phenol, alkyl ethers
 RL: ANST (Analytical study)
 (in blood **platelet-activating factor**
 determination in body fluid by immunoassay)

IT 76901-00-3, **Platelet activating factor**
 acetylhydrolase
 RL: ANST (Analytical study)
 (inactivation of, by Tween 20, blood **platelet-**
activating factor immunoassay in relation to)

IT 931-56-6P, 1-Methoxycyclohexane 933-40-4P, 1,1-Dimethoxycyclohexane
 18751-83-2P, 6,6-Dimethoxyhexan-1-ol 25176-55-0P, Methyl-6,6-
 dimethoxyhexanoate 119142-18-6P 119142-19-7P 119142-20-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of blood **platelet-**
activating factor analogs)

IT 119142-21-1DP, methylated albumin conjugates
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as immunogen for blood **platelet-**
activating factor immunoassay)

IT 108-94-1, Cyclohexanone, reactions 149-73-5, Trimethylorthoformate
 119142-17-5, (R)-1-(Benzyloxy)-2,3-epoxypropane
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in preparation of blood **platelet-activating**
factor analogs)

IT 108-95-2D, Phenol, alkyl ethers
 RL: ANST (Analytical study)
 (in blood **platelet-activating factor**
 determination in body fluid by immunoassay)

IT 76901-00-3, **Platelet activating factor**
 acetylhydrolase
 RL: ANST (Analytical study)
 (inactivation of, by Tween 20, blood **platelet-**
activating factor immunoassay in relation to)

IT 931-56-6P, 1-Methoxycyclohexane 933-40-4P, 1,1-Dimethoxycyclohexane
 18751-83-2P, 6,6-Dimethoxyhexan-1-ol 25176-55-0P, Methyl-6,6-
 dimethoxyhexanoate 119142-18-6P 119142-19-7P 119142-20-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of blood **platelet-**
activating factor analogs)

IT 119142-21-1DP, methylated albumin conjugates
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as immunogen for blood **platelet-**
activating factor immunoassay)

IT 108-94-1, Cyclohexanone, reactions 149-73-5, Trimethylorthoformate
 119142-17-5, (R)-1-(Benzyloxy)-2,3-epoxypropane
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in preparation of blood **platelet-activating**
factor analogs)